Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling
- 1 April 2021
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 554, 206-213
- https://doi.org/10.1016/j.bbrc.2020.12.055
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Specific inhibition of Notch1 signaling suppresses properties of lung cancer stem cellsJournal of Cancer Research and Therapeutics, 2019
- Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcomaOncotarget, 2017
- Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of CancerClinical Cancer Research, 2017
- WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathwayOncotarget, 2016
- Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G 0 /G 1 accumulation and ROS generationEnvironmental Toxicology and Pharmacology, 2016
- Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signalingOncotarget, 2016
- A Phase II Trial of Tideglusib in Alzheimer's DiseaseJournal of Alzheimer's Disease, 2015
- Elevation in 5-FU-induced apoptosis in Head and Neck Cancer Stem Cells by a combination of CDHP and GSK3β inhibitorsJournal of Oral Pathology & Medicine, 2014
- Regulation of Notch1/NICD and Hes1 Expressions by GSK-3α/βMolecules and Cells, 2009
- Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signalingCancer Letters, 2008